Navigation Links
Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy

ctivity of certain genes in the body.

Previous studies have shown that HDAC inhibitors can increase the amount of SMN2 expression in cultured cells and that treating pregnant mice with an HDAC inhibitor can increase the survival of their babies with SMA. Preliminary clinical trials are now underway to test several HDAC inhibitors in children who have SMA. However, the drugs in those clinical trials are weak HDAC inhibitors with other biological effects that may limit their usefulness for treating this disease. More importantly, none of the previous studies has demonstrated that HDAC inhibitors can extend survival when delivered after symptoms appeared.

In the new study, the investigators tested TSA, which is a potent HDAC inhibitor, in cells from SMA patients and in a mouse model of SMA. They found that the drug increased the amount of SMN2 gene activity in both the cultured cells and the mouse model.

Next, the researchers gave daily injections of TSA to the SMA mice, starting when the mice were 5 days old. By that time, the mice showed clear symptoms of disease: they were significantly underweight and they had a markedly impaired righting reflex, or ability to get on their feet after being placed on their backs. The treated mice lived 19 percent longer, on average, than mice that did not receive TSA. About three-fourths of the treated mice had improved survival compared to control mice. The other fourth showed no improvement.

The treated mice had less weight loss and better righting reflexes, walking ability, and forelimb grip strength than mice that did not receive TSA. Examination showed that the TSA-treated mice also had larger neurons in the spinal cord, thicker muscle fibers, and more muscle mass than untreated mice.

"This is a proof-of-concept experiment," says Dr. Sumner. "It clearly demonstrates that this treatment can ameliorate the disease in mice." While the results are exciting, there are still no stud
'"/>




Page: 1 2 3

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis

Post Your Comments:
(Date:11/22/2009)... HealthSmart, an innovative healthcare benefit...ccessfully completed a recapitalization with Silve...r lenders. Silver Point Capital, L.P. is a privat... This recapitalization allows the Company to cont...y. , , (PRWEB) November ...
(Date:11/21/2009)...N, Nov. 21 Tonight, in ...to Senator Reid,s version of the government takeov... items included in this bill; like the public opti...nment funding for elective abortion, which is the ...ly the bill provides subsidies for private plans t...
(Date:11/21/2009)...ON, Nov. 21 A regional ...ocerciasis (river blindness) in the Americas has s... in recent years, as evidenced by a 31% decrease i...ministration in six endemic countries. Results we...e American Society of Tropical Medicine and Hygien...
(Date:11/21/2009)... Innovative medical apparel company launches m... San Clemente, Calif. (PRWEB) Nov...ough medical apparel, today announced the launch o...ica 2009, a leading international trade fair for t...edelita inaugurates its men,s collection with thre...
(Date:11/21/2009)... Linwood Group ask whether there is a secret t... , London, UK (PRWEB) Nove... to one in three of the adult UK population drinki...lcohol-related liver disease*, it is hardly a surp...itation programmes and residential centres for hel...
Breaking Medicine News(10 mins):Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4
...y, ALLEGAN, Mich., May 21 Perrigo Company,(Nasda...ed into a,collaborative agreement with Cobrek Phar...maceuticals Inc., a privately owned company that s... foam, a $34,million branded pharmaceutical produc...
.... (NYSE: CNO ) at the company,s annual meeting to...expiring at next year,s annual meeting;, -- A... incorporation to eliminate the plurality voti...LP as the company,s independent registered pub...
...have identified a biological explanation for the l...allergy and asthma in childhood. They will present...2008 International Conference in Toronto on Tuesda...d cord blood levels of IL-13, a Th2 type cytokine,...
...d: CRDT), a leading healthcare staffing company, h...arch 31, 2008., Revenue in the quarter was $10,57...revenue of $9,806,540 and an increase of 31% over ...urth quarter of 2007 and $1,712,150 in the first q...
... in very young children may cause some of the adve...er children and adults with the condition, accordi...r findings at the American Thoracic Societys 2008 ...st and sleep specialist who led the study at Ben-G...
...turer,of laser and light-based skin sculpting and ...he introduction of an additional fractional,device...s two new features,-- significantly higher speed, ...aster than competitive instruments, ProFractional-...
Other Medicine News:Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 2Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 3Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 4Health News:Possible biological explanation for C-Section-linked allergies and asthma found 2Health News:Crdentia Announces 2008 First Quarter Results 2Health News:Crdentia Announces 2008 First Quarter Results 3Health News:Crdentia Announces 2008 First Quarter Results 4Health News:Crdentia Announces 2008 First Quarter Results 5Health News:Crdentia Announces 2008 First Quarter Results 6Health News:Crdentia Announces 2008 First Quarter Results 7Health News:Sciton Introduces ProFractional-XC(TM), High-Speed, Dual-Mode Fractional Laser 2
(Date:11/20/2009)..., MINNEAPOLIS, Nov. 20 B...sults for its first quarter ended September 30, 20...uted share, on revenues of $3,263,000. This compa...ted share, on revenues of $3,168,000 for the first...st quarter results, Biotel President and CEO Steve...
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-U...mes article that questions why currently availabl...ancers are being ignored, ECRI Institute, an indep...ap to the evidence on Finasteride for Prevention ... November 13, 2009, New York Times article, " Dr...
(Date:11/20/2009)..., MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCall/...s Division is pleased to announce the signing of a...tates Department of Defense that may lead to the c...revolutionize the treatment of the limbs of soldie...ar, the Defense Advanced Research Projects Agency ...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 1Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 1National new biology initiative offers potential for remarkable and far reaching benefits 9968 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 3The Vitality Group Joins Efforts to Improve Health of U S Workforce 57525 1The Vitality Group Joins Efforts to Improve Health of U S Workforce 57525 2
...NTEREY, Calif., Nov. 26 PARI Pharma,s eFlow,elect... GILD ) recent New,Drug Application (NDA) submitta...or marketing approval of aztreonam lysine for inha... for inhalation, delivered by eFlow, is,an investi...stic fibrosis,(CF) who have pulmonary Pseudomonas ...
...Three large, randomized Phase III trials of VELCAD... as oral presentations at the American ...AMBRIDGE, Mass., Nov. 26 Millennium,Pharmaceutica... data from,more than 130 abstracts of VELCADE clin...9th ASH Annual Meeting in Atlanta, Georgia, Decemb...
Other Medicine Technology:PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 2PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
Prechopper curved
Medina Irrigating Nucleus Chopper
Rosen Irrigating Nucleus Chopper
Agarwal Irrigating Nucleus Chopper
Medicine Products: